Business
Interim Statement
Interim Statement.
About this update from Bioventix Plc
[{"type":"text","content":"\n \n \n \n Bioventix plc\n \n \n \n (\"Bioventix\" or the \"Company\")\n \n \n \n \n \n \n Unaudited Interim Results for the six months ended 31 December 2022\n \n \n \n \n \n \n \n \n \n Bioventix plc (BVXP) (\"Bioventix\" or \"the Company\"), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its unaudited interim results for the six-month period ended 31 December 2022.\n \n \n \n \n \n \n \n \n Highlights\n \n \n \n \n \n \n ·\n Revenue up 25% to £5.9 million (2021: £4.7 million)\n \n \n ·\n Profit before tax up 27% to £4.5 million (2021: £3.6 million)\n \n \n ·\n Closing cash balances of £5.2 million (2021 £5.1 million)\n \n \n ·\n Interim dividend up 20% to 62p per share (2021: 52p)\n \n \n \n \n \n \n CHAIRMAN AND CHIEF EXECUTIVE'S STATEMENT\n \n \n \n \n \n \n \n Business review\n \n \n \n \n \n \n Bioventix is pleased to report revenues for the half-year of £5.9 million (2021: £4.7 million). Sales of physical product have performed well and revenues from our vitamin D antibody and other core antibodies have all increased as anticipated. \n \n \n \n \n \n Sales relating to troponin antibodies grew significantly once again during the period. The continued roll-out of high sensitivity troponin tests provides further encouragement for our future sales in this area. \n \n \n \n \n \n Total profits before tax for the half-year were up 27% to £4.5 million (2021: £3.6 million). The cash balances at 31 December 2022 stood at £5.2 million (2021 £5.1 million). \n \n \n \n \n \n Our research activities continue in line with the plans we described in our 2022 annual report. \n \n \n \n \n \n We continue to await news and critical data from both of our partners in Oslo; on our secretoneurin project with CardiNor for enhancing cardiac diagnostics and on our amyloid beta project with Pre-Diagnostics in Alzheimer's diagnostics. We hope to have more news on these two projects during 2023. \n \n \n \n \n \n A considerable amount of our laboratory resource has been focused on the Tau biomarker which shows exciting potential in neurodegenerative diseases including Alzheimer's disease. We continue to creat...